Highest-materiality recent filing
Evolus licenses Profhilo for U.S. skin-quality market; no upfront payment
Exclusive license to develop and commercialize Profhilo in the U.S. for aesthetics and dermatology.
Brady Stewart elected with 38,479,626 for (1,662,228 withhold); Vikram Malik with 21,310,653 for (18,831,201 withhold).
Evolus Q1 2026 rev $73.1M (+7% YoY); Adjusted EBITDA positive $0.6M
Global net revenue $73.1M (+7% vs Q1 2025); GAAP operating loss narrowed to $6.8M from $15.2M.
Evolus reclassifies Vikram Malik to Class II director after board refresh
Simone Blank stepped down from the Board to support refreshment efforts, causing class imbalance.
Evolus Q4 GAAP operating income $4.2M; FY25 revenue $297.2M up 12%; guides 2026 rev $327-337M
Q4 GAAP operating income $4.2M vs loss $2.3M YoY; Non-GAAP operating income $7.1M, above guidance.
Evolus Q4 2025 prelim rev $88.6-90.6M (+12-15%); 2026 rev guide $327-337M; targets profitability
Preliminary Q4 2025 net revenue $88.6M-$90.6M, 12-15% YoY growth; positive non-GAAP op income $5M-$7M.
Evolus Q3 revenue $69M (+13% YoY); expects Q4 non-GAAP operating profit $5-7M
Q3 total net revenue $69.0M, up 13% YoY; global Jeuveau $63.2M, Evolysse $5.7M.
Evolus appoints Tatjana Mitchell as CFO effective Sept 8, 2025
Appointed Tatjana Mitchell as CFO; previously SVP Finance at Experian, CFO of Experian Consumer Services.
Q2 net revenue $69.4M, up 4% YoY; GAAP op loss $10.2M vs $7.7M loss YoY; non-GAAP op loss $7.9M vs $1.1M income.
Evolus annual meeting elects directors; Director Blank departs in planned transition
Simone Blank stepped down from board effective June 5, 2025, as part of planned refreshment; no disagreement.
Evolus CFO Sandra Beaver resigns effective June 13, 2025, to join private mental health tech company
Sandra Beaver resigns as CFO effective June 13, 2025; no disagreement with the company on operations or accounting.
Evolus Q1 revenue $68.5M (+15.5% YoY); reaffirms FY2025 guidance; Evolysse launch strong
Q1 global net revenue $68.5M, up 15.5% from Q1 2024 on higher volumes and market share gains.
Evolus refinances with $250M credit facility, cuts interest cost by 350 bps
New $250M senior secured term loan replaces existing $125M facility; $150M drawn at closing, $100M incremental capacity available in two $50M tranches through Dec 31, 2026.
Record Q4 revenue $79.0M (+30% YoY); full-year $266.3M (+32% YoY).
Preliminary Q4 2024 net revenue $79.0M (+30% YoY); FY2024 net revenue $266.3M (+32% YoY) at top of guidance ($260-266M).
Evolus Q3 revenue $61.1M (+22% YoY); narrows FY2024 guidance to $260-266M
Q3 net revenue $61.1M, up 22% from $50.0M in Q3 2023; year-to-date growth 33%.
Total net revenue of $66.9M for Q2 2024, up 36% YoY from $49.3M.
Evolus appoints CooperCos CEO Albert White to board; Hayman steps down
Albert White III, CEO of CooperCompanies (COO), elected to Evolus board effective July 1, 2024.
Evolus stockholders approve 2024 ESPP and elect three Class III directors at annual meeting
Stockholders approved 2024 ESPP effective June 6, 2024, authorizing up to 579,648 shares with annual increases.
Evolus Q1 revenue up 42% YoY to $59.3M; on track for non-GAAP profitability in Q4 2024
Net revenue $59.3M (+42% YoY); gross margin 68.3%; non-GAAP loss from ops $0.9M, narrowing from Q4 2023's $3.7M.
Evolus directors Hayman and Blank plan to step down as part of board refreshment
Robert Hayman to step down upon identification and appointment of a replacement director.
Evolus prices public offering of 3.55M shares at $14.07/share; net proceeds ~$46.9M
Underwriters Leerink and Stifel purchase 3,554,000 shares at $13.2258/share; option for 533,100 more.
Evolus reports record Q4 revenue $61.0M (+40% YoY); guides to Q4 2024 profitability
Full-year 2023 net revenue $202.1M (+36% YoY); Q4 record $61.0M (+40% YoY).
Evolus reports preliminary FY2023 net revenue $202M, above guidance; guides FY2024 $255-265M
Preliminary Q4 2023 net revenue ~$61M, up 40% YoY and 22% sequential; FY2023 net revenue ~$202M, +36% YoY.
Evolus signs exclusive deal with Symatese for four dermal fillers in Europe; issues 610,000 shares
Exclusive rights to distribute Lift, Smooth, Sculpt, and Lips fillers under Estyme® brand in 50 European countries.
Evolus reports record Q3 revenue $50M (+48% YoY); raises FY guidance; 40U shows 26-week duration
Net revenue of $50.0M, up 48% from $33.9M in Q3 2022; operating cash burn only $0.9M.
Evolus Q2 revenue $49.3M (+33% YoY); raises FY2023 guidance to $185-195M
Net revenue $49.3M, up 33% YoY; loss from ops $15.1M including $4.4M milestone payment.
Evolus raises FY2023 revenue guidance to $185-195M, Q2 revenue $49.3M (+33% YoY)
Q2 net revenue $49.3M, up 33% YoY, a new quarterly record.
Evolus shareholders approve doubling authorized shares to 200M, elect Blank and Stewart as directors
Stockholders approved increase in authorized common shares from 100M to 200M (45.5M for, 0.97M against).
Evolus Q1 revenue up 23% to $41.7M; enters filler market; raises 2028 outlook to $700M
Q1 net revenue $41.7M, +23% YoY; reaffirms FY2023 guidance of $180-190M.
Evolus discloses no deposits at SVB or Signature Bank
Evolus holds no deposits at Silicon Valley Bank or Signature Bank.
Evolus Q4 revenue $43.6M (+26% YoY); FY22 revenue $148.6M (+49%); reaffirms FY23 guidance $180-190M
Q4 net revenue $43.6M, up 26% YoY; FY22 net revenue $148.6M, up 49% YoY (top end of guidance).
Q4 2022 prelim net revenue ~$43.6M (+26% YoY); FY2022 ~$148.6M (+49% YoY), at top end of $143-150M guidance.
Evolus amends Daewoong supply pact: exits Russia, revamps Europe pricing
Evolus exits Russia; all rights to neurotoxin distribution revert to Daewoong.
Evolus extends $50M undrawn tranche availability to Dec 2023
Second $50M tranche under $125M term loan facility now available until Dec 31, 2023 (extended from Dec 31, 2022).
Evolus Q3 revenue +27% to $33.9M; reiterates FY2022 guidance at top end
Revenue $33.9M (+27% YoY); deferred $3.5M incremental due to 'Switch Your Tox' campaign, understating growth.
Evolus appoints Sandra Beaver as CFO effective September 5, 2022
Sandra Beaver appointed CFO; most recently SVP of Finance at Experian, 17 years at IGT.
Evolus Q2 revenue $37.2M (+42% YoY); reaffirms FY upper-end guidance $143-150M
Q2 net revenue $37.2M, up 42% YoY; gross margin 55.4% (adj. 57.4%); operating loss $21.3M.
Evolus stockholders elect three Class I directors, ratify EY as auditor at 2022 annual meeting
David Gill, Robert Hayman, and Peter Farrell elected as Class I directors for three-year terms ending 2025.
Evolus Q1 revenue jumps 177% to $33.9M; guides to upper end of FY2022 range $143-150M
Net revenue $33.9M vs $12.2M in Q1 2021, driven by higher volumes and slightly higher ASP.
Evolus CFO Lauren Silvernail to retire effective May 31, 2022; successor search underway
CFO Lauren Silvernail to retire on May 31, 2022, for personal reasons; no disagreements with company.
Evolus Q4 revenue $34.7M (+68% YoY); 2021 revenue $99.7M (+76%); 2022 guidance $143-150M reaffirmed
Q4 2021 net revenue $34.7M, up 68% from Q4 2020; full-year revenue $99.7M, up 76% over 2020.
Evolus reports Q4 preliminary revenue $34.7M (+68% YoY), guides 2022 revenue $143-150M
Q4 2021 preliminary net revenue $34.7M, up 68% YoY; full-year 2021 revenue $99.7M, up 76% YoY.
Evolus appoints Brady Stewart to Board of Directors effective Jan 5, 2022
Appointed Brady Stewart as Class II director, term expiring at 2023 annual meeting.
Evolus enters $125M credit facility with Pharmakon Advisors; initial $75M draw
$75M drawn at close; up to $50M additional tranche available until Dec 31, 2022.
Evolus Q3 revenue $26.7M (+58% YoY); record sales; initiates extra-strength Jeuveau Phase II
U.S. net revenue of $26.7M, up 58% YoY; total net revenue up 51% to $26.7M.
Evolus Q2 net revenue up 235% YoY to $26.1M; raises gross margin target
Jeuveau net revenue of $26.1M, up 235% from $7.8M in Q2 2020.
Simone Blank voluntarily stepped down from the board of directors of the Company (the “Board”) effective on June 5, 2025, as part of a planned board refreshment and transition.
On May 27, 2025, Evolus, Inc. (the “Company”) announced that Sandra Beaver had informed the Company of her decision to voluntarily resign from her position as the Chief Financial Officer, effective as of June 13, 2025, to pursue another opportunity.
Robert Hayman voluntarily stepped down from the Board effective upon Mr. White’s appointment on July 1, 2024 as part of a planned board refreshment and transition.
The Board of Directors (the “Board”) of Evolus, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee (the “Committee”), appointed Albert G. White III as a member of the Board, effective immediately.
Mr. Hayman notified the Board that he will step down from his position on the successful identification and appointment of a replacement director.
Ms. Blank notified the Board that she will step down from her position on the earlier of: (i) the Company’s Annual Shareholder Meeting occurring in 2025, or (ii) the successful identification and appointment of a replacement director, whichever occurs first.
On August 30, 2022, Evolus, Inc. (the “Company”) announced that, effective September 5, 2022, its Board of Directors (the "Board') appointed Sandra Beaver to serve as the Company’s Chief Financial Officer.
On March 3, 2022, Evolus, Inc. (the “Company”) announced that Lauren Silvernail, will retire as the Company’s Chief Financial Officer and Executive Vice President, Corporate Development effective as of May 31, 2022
Effective January 5, 2022, the Board of Directors (the “Board”) of Evolus, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee (the “Committee”), appointed Brady Stewart as a member of the Board, effective immediately.
Max materiality 0.85 · Median 0.70 · Most common event earnings